title: Effects of long-term intake of lactotripeptides on cardiovascular risk factors in hypertensive subjects.
abstract: OBJECTIVE
  Lactobacillus helveticus LBK-16H-fermented milk products containing tripeptides isoleucine-proline-proline and valine-proline-proline lower blood pressure in hypertensive subjects using office and home blood pressure registration. The present study was aimed to evaluate the effects of two doses of these lactotripeptides on 24-h ambulatory blood pressure and lipidomics profiles in mildly hypertensive subjects.
  
  
  METHODS
  In a randomized, double-blind, placebo-controlled parallel group study, 89 mildly hypertensive subjects ingested, after a 1-month run-in period, a fermented milk drink with 5 mg per day of lactotripeptides during 3 months, and a milk drink with 50 mg per day of lactotripeptides for the following 3 months, or a placebo milk drink without lactotripeptides. Ambulatory blood pressure (24 h) was recorded at baseline and at the end of the intervention periods. Lipidomics profiles were characterized before and after the 6-month intervention.
  
  
  RESULTS
  After the second intervention period (50 mg per day of lactotripeptides), systolic and diastolic 24-h blood pressures decreased significantly in the peptide, but not in the placebo group. However, the treatment effects -2.6 mm Hg (95% confidence interval (CI): -5.7 to 0.4) in systolic and -1.3 mm Hg (95% CI: -3.4 to 0.8) in diastolic blood pressure did not reach statistic significance. Ingestion of 5 mg per day of lactotripeptides for 3 months did not lower blood pressure. The peptide group was dominated by decrease in multiple phospholipids (PL).
  
  
  CONCLUSIONS
  Ingestion of fermented milk with daily dose of 50 mg of lactotripeptides appears to lower elevated blood pressure slightly from the baseline, but not significantly compared with the placebo group and to induce significant decreases in multiple PL.
authors.affiliation: Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Jauhiainen
authors.forename: L
authors.initials: L
authors.lastname: Niittynen
authors.forename: M
authors.initials: M
authors.lastname: Orešič
authors.forename: S
authors.initials: S
authors.lastname: Järvenpää
authors.forename: T P
authors.initials: TP
authors.lastname: Hiltunen
authors.forename: M
authors.initials: M
authors.lastname: Rönnback
authors.forename: H
authors.initials: H
authors.lastname: Vapaatalo
authors.forename: R
authors.initials: R
authors.lastname: Korpela
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology; D043302:Cultured Milk Products / Q000737:chemistry* / Q000378:metabolism / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D052198:Lactobacillus helveticus; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood*; D012307:Risk Factors
chemical_list: D000959:Antihypertensive Agents; D009842:Oligopeptides; D010743:Phospholipids; C489032:isoleucyl-prolyl-proline; C489031:valyl-prolyl-proline